Shengling Fu

991 total citations
37 papers, 746 citations indexed

About

Shengling Fu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Shengling Fu has authored 37 papers receiving a total of 746 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Shengling Fu's work include Cytokine Signaling Pathways and Interactions (12 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Growth Hormone and Insulin-like Growth Factors (5 papers). Shengling Fu is often cited by papers focused on Cytokine Signaling Pathways and Interactions (12 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Growth Hormone and Insulin-like Growth Factors (5 papers). Shengling Fu collaborates with scholars based in China and United States. Shengling Fu's co-authors include Jiayuh Lin, Xiangning Fu, Yixin Cai, Ni Zhang, Lequn Li, Yi Gao, Xiang Chen, Hui‐Wen Lo, Yongde Liao and Huey‐Jen Lin and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Scientific Reports.

In The Last Decade

Shengling Fu

36 papers receiving 740 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shengling Fu China 14 403 272 195 158 155 37 746
Mateusz Olbromski Poland 15 242 0.6× 354 1.3× 136 0.7× 170 1.1× 116 0.7× 43 717
Myriam Kossaï France 10 279 0.7× 277 1.0× 173 0.9× 258 1.6× 102 0.7× 36 768
Marco Puzzoni Italy 16 438 1.1× 213 0.8× 174 0.9× 159 1.0× 102 0.7× 50 737
Oliver J. Stoetzer Germany 14 206 0.5× 256 0.9× 97 0.5× 113 0.7× 97 0.6× 29 625
Tommasina Biscotti Italy 13 430 1.1× 182 0.7× 233 1.2× 208 1.3× 59 0.4× 21 690
Yu‐zhong Duan China 12 320 0.8× 306 1.1× 107 0.5× 201 1.3× 263 1.7× 26 713
Xianlu Zhuo China 17 288 0.7× 496 1.8× 167 0.9× 210 1.3× 65 0.4× 69 841
Michiko Imamura Japan 17 367 0.9× 167 0.6× 87 0.4× 196 1.2× 135 0.9× 36 653

Countries citing papers authored by Shengling Fu

Since Specialization
Citations

This map shows the geographic impact of Shengling Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengling Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengling Fu more than expected).

Fields of papers citing papers by Shengling Fu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengling Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengling Fu. The network helps show where Shengling Fu may publish in the future.

Co-authorship network of co-authors of Shengling Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Shengling Fu. A scholar is included among the top collaborators of Shengling Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengling Fu. Shengling Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Song, Xiaozhen, et al.. (2023). “Low-age, low-frequency” lung cancer screening strategies maybe adaptable to the situation in China. BMC Surgery. 23(1). 367–367. 1 indexed citations
3.
Wei, Ping, Shengling Fu, Yangkai Li, et al.. (2021). A new minimally invasive technique for correction of pectus carinatum. Journal of Cardiothoracic Surgery. 16(1). 280–280. 1 indexed citations
4.
Chen, Xiang, Li Pan, Jia Wei, et al.. (2021). LLL12B, a small molecule STAT3 inhibitor, induces growth arrest, apoptosis, and enhances cisplatin-mediated cytotoxicity in medulloblastoma cells. Scientific Reports. 11(1). 6517–6517. 14 indexed citations
5.
Wang, Qi, Ping Wei, Yixin Cai, et al.. (2019). Modified McKeown procedure with uniportal thoracoscope for upper or middle esophageal cancer: initial experience and preliminary results. Journal of Thoracic Disease. 11(11). 4501–4506. 7 indexed citations
6.
Tian, Jilai, Xiang Chen, Shengling Fu, et al.. (2019). Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer. Breast Cancer Research and Treatment. 175(3). 553–566. 59 indexed citations
7.
Fu, Shengling, Xiang Chen, Hui‐Wen Lo, & Jiayuh Lin. (2019). Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer. Cancer Letters. 448. 11–19. 55 indexed citations
8.
9.
Chen, Xiang, Shengling Fu, Jilai Tian, et al.. (2018). Abstract 864: Repurposing FDA-approved drug bazedoxifene as a novel inhibitor of IL-6 signaling for triple-negative breast cancer. Cancer Research. 78(13_Supplement). 864–864. 2 indexed citations
10.
Cai, Yixin, Ying Han, Ni Zhang, et al.. (2017). Modular Uniportal Video-Assisted Thoracoscopic Lobectomy and Lymphadenectomy: A Novel Pattern of Endoscopic Lung Cancer Resection. Journal of Laparoendoscopic & Advanced Surgical Techniques. 27(12). 1230–1235. 3 indexed citations
11.
12.
Fu, Shengling, Hongbo Tang, Yongde Liao, et al.. (2016). Expression and Clinical Significance of Insulin-Like Growth Factor 1 in Lung Cancer Tissues and Perioperative Circulation from Patients with Non-Small-Cell Lung Cancer. Current Oncology. 23(1). 12–19. 17 indexed citations
13.
Li, Jing, Qianqian Yu, Shengling Fu, et al.. (2016). A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients. Journal of Cancer Research and Clinical Oncology. 142(7). 1621–1628. 5 indexed citations
14.
You, Liangkun, Changyu Liu, Hexiao Tang, Yongde Liao, & Shengling Fu. (2014). Advances in Targeting Insulin-like Growth Factor Signaling Pathway in Cancer Treatment. Current Pharmaceutical Design. 20(17). 2899–2911. 11 indexed citations
15.
Liao, Yongde, Chao Zhang, Guang Chen, et al.. (2014). Fulvestrant-Mediated Inhibition of Estrogen Receptor Signaling Slows Lung Cancer Progression. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 22(1). 13–20. 15 indexed citations
16.
Huang, Liu, Fengju Chen, Yangyang Chen, et al.. (2014). Thymidine phosphorylase gene variant, platelet counts and survival in gastrointestinal cancer patients treated by fluoropyrimidines. Scientific Reports. 4(1). 5697–5697. 11 indexed citations
17.
Wei, Ping, Chunjiao Xia, Shengling Fu, et al.. (2014). Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma. Tumor Biology. 36(2). 693–700. 6 indexed citations
18.
Zhang, Ni, Qinzi Xu, Yixin Cai, Shengling Fu, & Xiangning Fu. (2013). Operation mode and evolution of full thoracoscopic esophagectomy in treatment of esophageal carcinoma. 29(6). 323–325. 1 indexed citations
19.
Fu, Shengling, Yongde Liao, Wenyang Jiang, et al.. (2013). Association of preoperative serum IGF- I concentration with clinicopathological parameters in patients with non-small cell lung cancer. Journal of Huazhong University of Science and Technology [Medical Sciences]. 33(2). 224–227. 6 indexed citations
20.
Wang, Ying, et al.. (2009). ANAPLASTIC LARGE CELL LYMPHOMA WITH PRIMARY INVOLVEMENT OF SKELETAL MUSCLE: A Rare Case Report and Review of the Literature. Pediatric Hematology and Oncology. 26(3). 142–149. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mateusz Olbromski Breakdown of academic impact, for papers by Myriam Kossaï Breakdown of academic impact, for papers by Marco Puzzoni Breakdown of academic impact, for papers by Oliver J. Stoetzer Breakdown of academic impact, for papers by Tommasina Biscotti Breakdown of academic impact, for papers by Yu‐zhong Duan Breakdown of academic impact, for papers by Xianlu Zhuo Breakdown of academic impact, for papers by Michiko Imamura
Rankless by CCL
2026